
Opinion|Videos|March 31, 2025
The Evolving Landscape for Atopic Dermatitis Treatment
Panelists discuss how the approval of dupilumab and subsequent biologics for moderate to severe atopic dermatitis has fundamentally transformed the treatment landscape by providing targeted, effective options with favorable safety profiles that address underlying disease pathways, shifting from symptomatic management toward long-term disease control, raising expectations for treatment outcomes, reducing reliance on systemic immunosuppressants, enabling personalized therapy based on specific inflammatory pathways, and establishing new standards for efficacy that emphasize not just skin clearance but also rapid itch relief and quality-of-life improvement.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Since the approval of dupilumab, how has the availability of biologics for the treatment of moderate to severe disease in recent years reshaped the treatment paradigm for atopic dermatitis?
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
Monthly PVX108 Raises Peanut Tolerance in Children, With Brian Vickery, MD
5

